Search
Search Results
##search.searchResults.foundPlural##
-
DEFERASIROX: OVER A DECADE OF EXPERIENCE IN THALASSEMIA
3301PDF: 1698HTML: 403 -
-
MYELODYSPLASTIC SYNDROMES AND IRON CHELATION THERAPY
3899PDF: 1373HTML: 2189Fig.1: 279Fig. 2: 264 -
THERAPEUTIC VALUE OF COMBINED THERAPY WITH DEFERASIROX AND SILYMARIN ON IRON OVERLOAD IN CHILDREN WITH BETA THALASSEMIA
2875PDF: 898HTML: 15035Therapeutic Value of Combined Therapy with Deferasirox and Silymarin on Iron Overload in Children with Beta Thalassemia: 378 -
THE HISTORY OF DEFERIPRONE (L1) AND THE COMPLETE TREATMENT OF IRON OVERLOAD IN THALASSAEMIA The history and roles of deferiprone
2722PDF: 1679HTML: 731 -
NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES
2132PDF: 1987HTML: 812 -
GLUCOSE HOMEOSTASIS AND ΑSSESSMENT OF Β-CELL FUNCTION BY 3-HOUR ORAL GLUCOSE TOLERANCE (OGTT) IN PATIENTS WITH Β-THALASSEMIA MAJOR WITH SERUM FERRITIN BELOW 1,000 NG/DL: RESULTS FROM A SINGLE ICET-A CENTRE OGTT in thalassemia and iron overload
4131PDF: 1216HTML: 476 -
PREVENTION OF ? THALASSEMIA IN NORTHERN ISRAEL - A COST-BENEFIT ANALYSIS.
3333PDF: 1441HTML: 11871 -
ZYGOMYCOSIS IN IMMUNOCOMPROMISED NON-HAEMATOLOGICAL PATIENTS
3033PDF: 1048HTML: 7521 -
FASTING PLASMA GLUCOSE LEVELS WITHIN THE HIGH NORMAL RANGE ARE ASSOCIATED WITH A SIGNIFICANTLY INCREASED RISK OF FUTURE DYSGLYCEMIA IN TRANSFUSION-DEPENDENT Β THALASSEMIA: A DECADE-LONG MULTICENTER RETROSPECTIVE ANALYSIS Higher normal fasting plasma glucose and glucose dysregulation in β- thalassemia
857PDF: 328Html: 53 -
GROWTH AND ENDOCRINE FUNCTION IN TUNISIAN THALASSEMIA MAJOR PATIENTS
5937PDF: 1099HTML: 490TABLE: 236FIGURES: 324 -
ASSOCIATION OF VDBP RS4701 VARIANT, BUT NOT VDR/RXR-? OVER-EXPRESSION WITH BONE MINERAL DENSITY IN PEDIATRIC ?-THALASSEMIA PATIENTS Vitamin D metabolic axis and BMD in ?-thalassemia
1404PDF: 795HTML: 297 -
A MULTICENTER ICET-A STUDY ON AGE AT MENARCHE AND MENSTRUAL CYCLES IN PATIENTS WITH TRANSFUSION-DEPENDENT THALASSEMIA (TDT) WHO STARTED EARLY CHELATION THERAPY WITH DIFFERENT CHELATING AGENTS. Age at menarche and menstrual cycles in patients with transfusion-dependent thalassemia.
906PDF: 617HTML: 190 -
VASCULAR ENDOTHELIAL GROWTH FACTOR IN CHILDREN WITH THALASSEMIA MAJOR PDF
1426PDF: 932HTML: 1145Figure 1 the correlation between frequency of blood transfusion and serum vascular endothelial growth factor (VEGF).: 232 -
POST-LOAD PLASMA GLUCOSE INCREASE (PG-GAP) AS A RISK FACTOR FOR DEVELOPING DYSGLYCEMIA IN PATIENTS WITH TRANSFUSION-DEPENDENT Β-THALASSEMIA (Β-TDT): RETROSPECTIVE ANALYSIS OVER 8 YEARS Post load plasma glucose increase and the risk of glucose dysregulation in thalassemia
642PDF: 299HTML: 179 -
Does splenectomy influence the development of Hypothyroidism in Transfusion Dependent Thalassemia Patients? A retrospective study. Splenectomy in Hypothyroidism of TDT patients
1437PDF: 1031HTML: 347 -
STUDY OF SERUM HAPTOGLOBIN LEVEL AND ITS RELATION TO ERYTHROPOIETIC ACTIVITY IN BETA THALASSEMIA CHILDREN .
2501PDF: 1241HTML: 2626Study of serum haptoglobin level in thalassemia: 442Figures: 266 -
PATIENTS WITH HAEMOGLOBINOPATHIES AND CHRONIC HEPATITIS C: A REALLY DIFFICULT TO TREAT POPULATION IN 2016?
3040PDF: 1042HTML: 2124Cover letter: 226 -
THE PERFORMANCE OF HOMA 2 COMPARED TO DYNAMIC MARKERS OF INSULIN SECRETION AND SENSITIVITY/RESISTANCE FOR PREDICTING DYSGLYCEMIA IN TRANSFUSION-DEPENDENT Β-THALASSEMIA: THE EXPERIENCE OF A SINGLE CENTRE HOMA 2 and DYNAMIC MARKERS OF INSULIN SECRETION FOR PREDICTING DYSGLYCEMIA in TDT
241PDF: 289HTML: 62 -
CONCISE REVIEW ON THE FREQUENCY, MAJOR RISK FACTORS AND SURVEILLANCE OF HEPATOCELLULAR CARCINOMA (HCC) IN ?-THALASSEMIAS: PAST, PRESENT AND FUTURE PERSPECTIVES Thalassaemia transfusion dependent, Hepatitis C, hepatocarcinoma.
4447PDF: 1611HTML: 482 -
HEMATOPOIETIC STEM CELL TRNSPLANTATION IN THALASSEMIA AND RELATED DISORDERS
2008PDF: 532HTML: 4052 -
Should every patient with MDS get iron chelation – probably yes.
2430PDF: 1016HTML: 403 -
A A RETROSPECTIVE LONG-TERM STUDY ON AGE AT MENARCHE AND MENSTRUAL CHARACTERISTICS IN 85 YOUNG WOMEN WITH TRANSFUSION-DEPENDENT Β-THALASSEMIA (TDT) BORN BETWEEN 1965 AND 1995 Long-Term Study on Age at Menarche and Menstrual Characteristics in patients with TDT
1742PDF: 570HTML: 278







